(Q48575066)

English

Lack of correlations between plasma concentration of medroxyprogesterone acetate, hypothalamic-pituitary function, and tumour response in patients with advanced breast cancer.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

12 February 2018

http://europepmc.org/abstract/MED/3156002

Lack of correlations between plasma concentration of medroxyprogesterone acetate, hypothalamic-pituitary function, and tumour response in patients with advanced breast cancer. (English)

1 reference

Europe PubMed Central

12 February 2018

http://europepmc.org/abstract/MED/3156002

medroxyprogesterone acetate

1 reference

based on heuristic

inferred from title

author name string

D W Hedley

1

1 reference

Europe PubMed Central

12 February 2018

http://europepmc.org/abstract/MED/3156002

M Christie

2

1 reference

Europe PubMed Central

12 February 2018

http://europepmc.org/abstract/MED/3156002

R P Weatherby

3

1 reference

Europe PubMed Central

12 February 2018

http://europepmc.org/abstract/MED/3156002

I D Caterson

4

1 reference

Europe PubMed Central

12 February 2018

http://europepmc.org/abstract/MED/3156002

publication date

1 January 1985

1 reference

Europe PubMed Central

12 February 2018

http://europepmc.org/abstract/MED/3156002

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

12 February 2018

http://europepmc.org/abstract/MED/3156002

14

1 reference

Europe PubMed Central

12 February 2018

http://europepmc.org/abstract/MED/3156002

2

1 reference

Europe PubMed Central

12 February 2018

http://europepmc.org/abstract/MED/3156002

112-115

1 reference

Europe PubMed Central

12 February 2018

http://europepmc.org/abstract/MED/3156002

https://scigraph.springernature.com/pub.10.1007/bf00434347

0 references

The pharmacokinetics of high-dose medroxyprogesterone acetate (MPA) in the therapy of advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/3156002

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose medroxyprogesterone acetate in breast cancer resistant to endocrine and cytotoxic therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/3156002

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Progestin therapy of breast cancer: comparison of agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/3156002

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetic approach to the selection of dose schedules for medroxyprogesterone acetate in clinical oncology

1 reference

https://pubmed.ncbi.nlm.nih.gov/3156002

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of alcoholic cirrhosis with enzyme inducers

1 reference

https://pubmed.ncbi.nlm.nih.gov/3156002

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative pharmacokinetics of medroxyprogesterone acetate administered by oral and intramuscular routes

1 reference

https://pubmed.ncbi.nlm.nih.gov/3156002

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A radioimmunoassay for serum medroxyprogesterone acetate

1 reference

https://pubmed.ncbi.nlm.nih.gov/3156002

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assessment of response to therapy in advanced breast cancer. A project of the programme on clinical oncology of the International Union against Cancer, Geneva, Switzerland.

1 reference

https://pubmed.ncbi.nlm.nih.gov/3156002

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Advanced breast cancer: response to high dose oral medroxyprogesterone acetate.

1 reference

https://pubmed.ncbi.nlm.nih.gov/3156002

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Medroxyprogesterone acetate (MAP) relative bioavailability after single high-dose administration in cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/3156002

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Medroxyprogesterone acetate (MAP) plasma levels after multiple high-dose administration in advanced cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/3156002

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A possible new approach to the treatment of metastatic breast cancer: massive doses of medroxyprogesterone acetate

1 reference

https://pubmed.ncbi.nlm.nih.gov/3156002

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Medroxyprogesterone acetate improvement of the hepatic drug-metabolizing enzyme system in rats after chemical liver injury

1 reference

https://pubmed.ncbi.nlm.nih.gov/3156002

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Medroxyprogesterone acetate (MPA) plasma levels after oral and intramuscular administration in a long-term study

1 reference

https://pubmed.ncbi.nlm.nih.gov/3156002

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical trial of Δ1-testololactone (NSC 23759), medroxy progesterone acetate (NSC 26386) and oxylone acetate (NSC 47438) in advanced female mammary cancer:A report of the cooperative breast cancer group

1 reference

https://pubmed.ncbi.nlm.nih.gov/3156002

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/BF00434347

1 reference

Europe PubMed Central

12 February 2018

http://europepmc.org/abstract/MED/3156002

1 reference

Europe PubMed Central

12 February 2018

http://europepmc.org/abstract/MED/3156002

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48575066&oldid=1562741092"